Trial Profile
AIN 457, an anti-IL17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2009
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 27 Oct 2009 Status changed from active, no longer recruiting to completed.
- 20 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009)
- 07 Aug 2009 suspect that this trial is part of CTP 13021 but cannot confirm.